Rankings
▼
Calendar
DNLI
Denali Therapeutics Inc.
$3B
FY 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$331M
+204.7% YoY
Gross Profit
$331M
100.0% margin
Operating Income
-$197M
-59.5% margin
Net Income
-$145M
-43.9% margin
EPS (Diluted)
$-1.06
Cash Flow
Operating Cash Flow
-$358M
Free Cash Flow
-$371M
Stock-Based Comp.
$108M
Balance Sheet
Total Assets
$1.2B
Total Liabilities
$123M
Stockholders' Equity
$1.0B
Cash & Equivalents
$127M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$331M
$108M
+204.7%
Gross Profit
$331M
$108M
+204.7%
Operating Income
-$197M
-$341M
+42.3%
Net Income
-$145M
-$326M
+55.5%
← Q4 2022
All Quarters
Q1 2023 →
DNLI FY 2023 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena